Dossier de Presse CVO Madagascar

1. After evaluation of several criteria:
cure, adverse events, biological results ...
it has been concluded that:
70,45% of patients were
cured as of 14 days.
PROSPECTS
87,1%
70,45%
EFFICACY
These results represent a significant
breakthrough in the fight against
Covid-19. Madagascar with its
CURATIVE CVO PLUS offers a
complementary therapeutic tool to the
existing arsenal against the pandemic in
support of the vaccinal effort taken on a
worldwide basis. Often qualified as a
“bridge to the vaccine” this treatment
entirely conceived and produced in
Madagascar with local raw vegetal
materials ambitions not only to provide
support for lesser developed countries
with low vaccinal coverage but also
targets countries which are currently
experiencing the limits of the mass
vaccination strategy.
Pharmalagasy and its partners are
ready to commercialize CURATIVE
CVO PLUS globally and currently has a
50 Million treatment per year capacity in
Madagascar.
Pharmalagasy and its partners also take
this opportunity to thank the President of
Madagascar Andry RAJOELINA for his
vision and his support all along the project
which has allowed within one short year to
set up a flagship world level pharmaceutical
factory, to elaborate the curative formulation
for Covid-19 and also to finalize successful
phase 3 clinical trials following Good Clinical
Practice (GCP)
A last and sincere thanks for the support
provided by the World Health
Organization (WHO) for having from the
onset supervised the clinical trials of
CURATIVE CVO PLUS.
Holijaona RABOANA
President of the Board of Directors
PHARMALAGASY
Pierre RAOELINA ANDRIAMBOLOLONA
General Manager of PHARMALAGASY
CURE
CURATIVE CVO PLUS has
an 87,1% efficacy rate for the
treatment of Covid-19 for
mild to moderate formsafter
28 days of monitoring.
None of the patients under CURATIVE CVO
PLUS have developpped a severe form of
COVID-19 and all patients preserved their
hepathic,renal and metabolic functions.
PRESS RELEASE
These results should have been confirmed in
larger scale trials but it was concluded that a more
adapted galenic form was needed for large scale
distribution. It is to be noted that this phase 2 study
was undertaken in the context of an international
partnership involving Professor Dhanjay Jhurry
Vice Chancellor of the University of Mauritius, Dr.
Thomas Lodi Director of Integrative Oncology
(Thailand) and Dr. Nathan Goodyear Oasis of
Healing (Arizona U.S.)
In oder to promote traditional Malagasy
medicine and taking into account the availability in
large scale of Artemisia annua and Ravintsara
which are both produced locally in Madagascar,
CURATIVE CVO PLUS – an improved traditional
remedy- was formulated.
The CVO PLUS CURATIVE gel caps contain a
complex standardized extract of Artemisia
annua and also the Ravintsara essential oil.
Each gel cap is normalized in content of
artemisinin at 150 mg, in flavonoid components at
3,3 mg, in terpenic compounds at 4mg and in
eucalyptol at 7,1mg. Compared to raw plant
material used in tea formulations (tambavy in
Malagasy), the content of active principles is
constant and stable. In order to evaluate the
efficacy and the harmlessness of CURATIVE CVO
PLUS in the treatment of Covid-19 a phase 3
clinical trial was undertaken between the months
of January and May 2021.
The clinical trial protocols were elaborated and
supervised by the World Health Organization
(WHO) which approved it before roll out.
These clinical trials were then approved
by the ethics committee of Malagasy
biomedical research (CERBM) on December 17
2020 under the reference N° 073
MINSANP/SG/AGMED/CERBM. It was also
officially registered on the Pan African Trial
registry under the identification :
PACTR20210399597082.
The study involved 339 patients stricken by
Covid-19 with mild to moderate symptoms and
has followed Good Clinical Practice (GCP) an
international ethical and scientific quality standard
for designing, recording and reporting trials that
involve the participation of human subjects. The
dosage of CURATIVE CVO PLUS is composed of
3 gel caps per day for a duration of 15 days. Each
patient was strictly followed during a total of 28
days.
The Covid-19 pandemic caused by the
“SARS-CoV-2” virus is still propagating in the
world despite several anti-covid strategies and
notably that of mass vaccination. As of yet there is
no single specific medication allowing to cure this
disease. In several countries in the world, a race
against the clock is underway to vaccinate a large
portion of the population in order to prevent further
propagation of the virus and at the same time
prevent severe forms of the disease. It is also the
case for research undertaken to identify curative
medications which for the most part are already at
the clinical trial stage. Several clinical trial
validation steps are needed (phase 1 to 3) before
a particular treatment can reach
commercialization.
In Madagascar, after having consulted the
scientific community, the President of
Madagascar Andry RAJOELINA has given the
approval for research in Covid-19 therapies which
are based on Artemisia annua and its derivatives
to combat Covid-19.
A phase 2 clinical trial was undertaken to
evaluate the efficacy of 2 cocktails for the
treatment of Covid-19, artesunate injectable and
the other protocol consisting of both injectable
artesunate and vitamin C. These trials were
undertaken from July 2020 and concluded in
September 2020. The results of these trials
concluded that artesunate injectable taken on its
own had a higher efficacy compared to the
combination of artesunate and vitamin C.